Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04790240 · ClinicalTrials.gov registry record · Phase 1
Medical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID)
A Phase 1 study of Covid19 Virus Infection, sponsored by All Natural Medicine Clinic.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT04790240: Recruiting Phase 1 study of Covid19 Virus Infection, sponsored by All Natural Medicine Clinic.
NCT04790240 is a Phase 1 study of Covid19 Virus Infection that is actively recruiting participants, run by All Natural Medicine Clinic. The registered enrollment target is 100 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04790240, a Phase 1 study of Covid19 Virus Infection, is actively recruiting participants, sponsored by All Natural Medicine Clinic.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The human immune system is designed to protect individuals from external sources of infection and internal cell mutation. It works effectively and efficiently until inflammation disturbs its functioning. Once compromised by inflammation, the immune system loses its capacity to recognize antigens and dependably defend the body against disease and illness. When COVID-19 invades humans, it causes an immune-storm (cytokine-storm) that can directly damage the organ(s), leading to death. The virus is an antigen - a trigger - but it is not the actual reason that causes organ failure and death; instead, it is the body's over immune reaction that is the cause. In attempting to protect the body, the immune system overreacts to the antigen, which includes the infected cells, which causes a cytokine-storm, and the subsequent and rapid shut down of the infected individual's organ(s)' structure, leaving the body without sufficient strength or time to fight back. When the medical herbs join the body, it can slow down the immune reaction. Medical herbs benefit the physical body; they protect the cells and organism structure and mediate the immune response, allowing the T cells to kill the virus (mutated or not) internally. Such success has been achieved by the All Natural Medicine Clinic during pre-clinical trials. This clinical study's goal is to demonstrate that the immune system can be rebuilt and retrained, using natural medicine (i.e., medical herbs), to kill the virus without causing the immune storm, and to explore the mechanism by which these medical herbs, which have been used for thousands of years for healing, achieve results.
Primary Outcome
comparing imagen of lungs
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Inflammation (I)
- DIETARY_SUPPLEMENT Inflammation (II)
- DIETARY_SUPPLEMENT Inflammation (III)
- DRUG Standard of care
Study Locations (1)
Maryland
- All Natural Medicine Clinic, LLC - Rockville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-01-01 |
| Est. Completion | 2027-05-30 |
| Phase | Phase 1 |
What NCT04790240 shows while recruiting
NCT04790240 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% higher).
The record links to 1 condition, with Covid19 Virus Infection appearing as the primary indexed condition, and to 4 interventions - of which Inflammation (I) is the first listed.
NCT04790240 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT04790240 about?
NCT04790240 is a clinical study titled "Medical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID)". The human immune system is designed to protect individuals from external sources of infection and internal cell mutation. It works effectively and efficiently until inflammation disturbs its functioning. Once compromised by inflammation, the immune system loses its capacity to recognize antigens and...
What is the current status of trial NCT04790240?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2025-01-01. Estimated completion is 2027-05-30.
What conditions does trial NCT04790240 study?
This clinical trial studies the following conditions: Covid19 Virus Infection.
What interventions are being tested in trial NCT04790240?
The interventions under investigation include: Inflammation (I) (DIETARY_SUPPLEMENT), Inflammation (II) (DIETARY_SUPPLEMENT), Inflammation (III) (DIETARY_SUPPLEMENT), Standard of care (DRUG).
Who is sponsoring clinical trial NCT04790240?
This trial is sponsored by All Natural Medicine Clinic, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04790240 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04790240's enrollment target sits among peer trials
100 547th of 2000 higher than 1,411 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI